ESMO 2025 – Sanofi takes aim at Lutathera
But Perspective sinks again.
ESMO 2025 – Novartis looks for Pluvicto prostate Addition
But the ESMO discussant recommends against widespread use in hormone-sensitive disease.
ESMO 2025 preview – a bemarituzumab reckoning approaches
Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.
BeOne cashes in its Imdelltra royalty
Meanwhile, Royalty Pharma stakes $885m on $2.8bn sales by 2035.
FDA doubles down on overall survival
New draft guidance could see the agency getting ever stricter.
FDA red and green lights: June 2025
Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
ASCO 2025 preview – Itovebi strengthens its first-line claim
Roche’s PI3Kα inhibitor continues to pull away from Novartis’s Piqray.
